Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min

American Journal of Hematology

Volumn 88, Issue 11, 2013, Pages 944-947

  Auerbach, Michael ^a   Strauss, William ^b   Auerbach, Sarah ^a   Rineer, Stella ^a   Bahrain, Huzefa ^a  

^a Auerbach Hematology and Oncology   (United States)

^b AMAG PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; IRON DEXTRAN; METHYLPREDNISOLONE; STEROID; TRANSFERRIN;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CHEILITIS; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHROCYTE PARAMETERS; FEMALE; FERRITIN BLOOD LEVEL; FEVER; FLUSHING; FOLLOW UP; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MYALGIA; NAUSEA; OPEN STUDY; PERIORBITAL EDEMA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; STEROID THERAPY; STRIDOR; TACHYCARDIA; TACHYPNEA; TELEPHONE INTERVIEW; THORAX PAIN; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAL SIGN; WHEEZING; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; ARTHRALGIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTE INDICES; FEMALE; FERROSOFERRIC OXIDE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; MYALGIA; OFF-LABEL USE; PILOT PROJECTS; THERAPIES, INVESTIGATIONAL; TRANSFERRIN; YOUNG ADULT;

EID: 84886290523     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23534     Document Type: Article

References (16)

1. Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter Suppl 2012;2:279-335.
2. Chandler G, Harchowal J, MacDougall IC. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 2001;38:988-991.
3. Balakrishnan VS, Rao M, Kausz AT, et al. Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 2009;39:489-496.
4. Johnson AC, Becker K, Zager RA. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol 2010:299:F426-F435.
5. ®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011;78:480-491.
6. Auerbach M, Ballard H. Clinical use of intravenous iron: Administration, efficacy and safety. Hematol Am Soc Hematol Educ Program 2010;2010:338-347.
7. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980;243:1726-1731.
8. Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988;111:566-570.
9. Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three irondextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998;31:81-86.
10. Reddy CM, Kathula SK, Ali SA, et al. Safety and efficacy of total dose infusion of iron dextran in iron deficiency anemia. Clin Pract 2008;62:413.15.
11. ®) for the treatment of iron deficient anemia. Am J Hematol 2011;86:860-862.
12. Raj SV, Cressman M, Ford D, et al. Ferumoxytol treatment results in robust hemoglobin increases in iron deficiency anemia patients with a history of unsatisfactory oral iron therapy in a phase III, randomized, placebo-controlled trial. Blood 2012;120:Abstract 2098.
13. Hetzel D, Urboniene A, Bernard K, et al. Potential new treatment option for iron deficiency anemia patients with a history of unsatisfactory oral iron therapy- results of a phase III, randomized, open-label, active-controlled trial of ferumoxytol. Blood 2012;120:Abstract 2099.
14. Okam MM, Mandell E, Hevelone N, et al. Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol 2012;87:E123-E124.
15. Sabau D. Nowak ES, Bender JE, et al. Safety of a single administration of 1 gram of IV ferumoxytol in hemodialysis patients with iron deficiency anemia (IDA) [Abstract PUB-393] J Am Soc Nephrol Abstract Issue 21:2010.
16. Littlewood TJ. Intravenous or oral iron? Am J Hematol 2012;87:134-135.